SSO Hospitals

SSO Hospitals is an Indian healthcare provider specializing in advanced surgical oncology solutions, delivering tailored cancer treatment services through experienced medical professionals and state-of-the-art technology. Founded in 2020, SSO Hospitals is based in Mumbai, India, and focuses on providing specialized cancer treatment. The company has engaged in one total deal, raising USD 2. 8 million in funding from investors including 2070 Health and Everhope Oncology Private Limited on December 8, 2025.

SSO Hospitals operates independently without known subsidiaries or parent companies, and specific details regarding its founders or their previous ventures are not available. SSO Hospitals offers a range of surgical oncology services, including advanced procedures for breast, gastrointestinal, thoracic, head and neck, and gynecological cancers. The hospital utilizes laparoscopic and robotic surgeries aimed at improving patient outcomes by reducing recovery times. Their services are available to both individual patients and healthcare providers, with facilities in major cities like Mumbai and Ahmedabad to cater to diverse patient needs.

SSO Hospitals generates its revenue through a transactional model, charging patients for surgical consultations and procedures. This fee-for-service approach allows patients to pay directly or through insurance for surgical interventions, pre-operative assessments, and post-operative care. While specific pricing details are not disclosed, the institution is committed to providing comprehensive patient support, including assistance with insurance claims, optimizing both patient care and operational efficiency. Following its most recent funding round in December 2025, where SSO Hospitals raised USD 2.

8 million, the company plans to expand access to specialized cancer care. This funding will be directed towards enhancing service capabilities and potentially entering new markets. Specific details regarding upcoming product launches and targeted geographic regions for expansion have not been disclosed, but the focus remains on improving cancer treatment accessibility.